 some patients who are compliant with aspirin therapy owing to
aspirin resistance. There is some evidence that aspirin’s
reduced antithrombotic efﬁcacy may be more common
in patients who take enteric coated aspirin or lower dose
therapy (81 mg) compared with those taking uncoated
aspirin (325 mg).125 However, routine laboratory testing
for platelet reactivity is not supported by the evidence.1